Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Sells ex-China Rights for Two Drug Candidates in $531 Million Deal

publication date: Oct 21, 2013
In a blockbuster deal, Shanghai Fosun Pharma plans to sell ex-China rights for two drug candidates – one treating cancer, the other diabetes – to Sellas Clinicals Holding of Greece. Sellas will pay up to $531.4 million in clinical milestones, based on trials in the US and Europe. The cooperation agreement was signed between an indirect subsidiary of Fosun, Chongqing Fochon Pharma, and Sellas. More details....

Stock Symbol: (SHA: 600196; HK: 02196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital